Form 4: Entrada Therapeutics CFO Kory James Wentworth Reports Stock Transactions

Kory James Wentworth, CFO of Entrada Therapeutics, reports acquisition of restricted stock units and stock options, along with sales to cover tax obligations.

Summary

• On March 1, 2024, Kory James Wentworth, CFO of Entrada Therapeutics, was granted 30,900 restricted stock units (RSUs) and 46,800 stock options.
• The RSUs vest in four equal installments on March 1st of 2025, 2026, 2027, and 2028.
• The stock options vest 25% on March 1, 2025, and the remaining 75% vest in 36 equal monthly installments thereafter, fully vesting on March 1, 2028.
• Wentworth also sold shares of common stock on March 4 and 5, 2024, to cover tax withholding obligations related to the vesting of previously granted RSUs.
• These sales involved 339 shares at a weighted average price of $12.423, 405 shares at a weighted average price of $13.3673, and 1,471 shares at a weighted average price of $12.2788.
• Following these transactions, Wentworth directly owns 78,256 shares of common stock and 46,800 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions. The grants are positive, but the sales to cover taxes are a normal part of equity compensation.

Positives

• The grant of RSUs and stock options to the CFO aligns his interests with the long-term success of the company.
• The vesting schedules for both RSUs and stock options encourage continued service and commitment from the CFO.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules suggest a long-term commitment from the CFO.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide investors with insights into the actions of company executives and their confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation practices in the biotechnology industry, used to attract and retain key executives.
• Vesting schedules are typically structured to align executive compensation with long-term company performance, similar to practices at companies like Moderna and BioNTech.
• Sales of shares to cover tax obligations are a standard occurrence when equity awards vest, and the amounts sold by Wentworth appear reasonable in this context.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign of aligning management interests with company performance.
• Employees may see the CFO's transactions as part of the company's overall compensation strategy.

Key Dates